RCA
ATRA icon

Ranch Capital Advisors’s Atara Biotherapeutics ATRA Stock Holding History

Ranch Capital Advisors’s Portfolio ATRA Stock Details ATRA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-80
Closed -$36K – 186
2021
Q3 		$36K Hold
80
– – 0.02% 301
2021
Q2 		$31K Hold
80
– – 0.02% 394
2021
Q1 		$28K Hold
80
– – 0.02% 393
2020
Q4 		$39K Hold
80
– – 0.03% 332
2020
Q3 		$25K Buy
+80
New +$27.2K 0.02% 397

Other funds holding ATRA

BG
Baupost Group Boston, Massachusetts $5.42B AUM 22.93% 1-Year Est. Return
MC
Maverick Capital Dallas, Texas $11.3B AUM 76.6% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Ranch Capital Advisors's ATRA Position: Q4 2021 in Review

Ranch Capital Advisors sold out of Atara Biotherapeutics (ATRA) in Q4 2021, closing a stake of 80 shares — an estimated $36K sold.

Ranch Capital Advisors first reported a position in ATRA in Q3 2020 and held it in 5 quarters. The position peaked at $39K in Q4 2020. 139 funds tracked by Wall St. Rank hold ATRA as of Q4 2021.

  • Ranch Capital Advisors reported no remaining Atara Biotherapeutics position as of Q4 2021 after selling out during the quarter.
  • Ranch Capital Advisors sold 80 Atara Biotherapeutics shares in Q4 2021, an estimated $36K.
  • Ranch Capital Advisors first reported a position in Atara Biotherapeutics in Q3 2020 and held it in 5 quarters.
  • Ranch Capital Advisors's Atara Biotherapeutics position peaked at $39K in Q4 2020.
  • 139 funds tracked by Wall St. Rank held Atara Biotherapeutics as of Q4 2021.

Based on Ranch Capital Advisors's 13F filing for Q4 2021, filed 8 Feb 2022.